252 related articles for article (PubMed ID: 34115024)
1. Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study.
Chen IC; Chang WT; Hsu PC; Yeh YL; Zheng S; Huang YC; Lin CH; Tsai LM; Lin LJ; Liu PY; Liu YW
Medicine (Baltimore); 2021 Jun; 100(23):e26272. PubMed ID: 34115024
[TBL] [Abstract][Full Text] [Related]
2. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
[TBL] [Abstract][Full Text] [Related]
3. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
Yasaka M; Umeyama M; Kataoka H; Inoue H
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
[TBL] [Abstract][Full Text] [Related]
5. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
Mavrakanas TA; Garlo K; Charytan DM
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
[TBL] [Abstract][Full Text] [Related]
6. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On-label Doses of Apixaban: J-ELD AF Registry Subanalysis.
Okada M; Inoue K; Tanaka N; Sakata Y; Akao M; Yamashita T; Suzuki S; Okumura K;
J Am Heart Assoc; 2021 Aug; 10(15):e021224. PubMed ID: 34323123
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
10. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
Okumura K; Yamashita T; Suzuki S; Akao M;
Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
[TBL] [Abstract][Full Text] [Related]
12. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
[TBL] [Abstract][Full Text] [Related]
14. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study.
Inoue H; Umeyama M; Yamada T; Hashimoto H; Komoto A; Yasaka M
J Cardiol; 2020 Feb; 75(2):208-215. PubMed ID: 31421933
[TBL] [Abstract][Full Text] [Related]
17. Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real-Life Study.
Salameh M; Gronich N; Stein N; Kotler A; Rennert G; Auriel E; Saliba W
Clin Pharmacol Ther; 2020 Dec; 108(6):1265-1273. PubMed ID: 32558928
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
